- Discuss guideline-directed strategies to the management of low-grade, intermediate-risk non-muscle invasive bladder cancer (LG-IR-NMIBC).
- Evaluate the role of intravesical therapies in LG-IR-NMIBC, including established and emerging treatment options.
- Analyze case-based scenarios to apply evidence-based treatment options and evaluate decision-making in diverse patient presentations.
Navigating Low-Grade, Intermediate-Risk NMIBC
Thursday, September 25, 2025
7:00-9:00 PM ET
Ocean Prime 2915 Coolidge Hwy, Troy, MI 48084
HRA® offers compensation of $500 to physicians for your consultative contributions during the event discussions, responses to polling questions and completion of a post-event survey.
Please note: this is a non-CME, unsponsored program. All content is independently developed by the Urology Times® team.
OVERVIEW
Urology Times® Clinical Forum are collaborative, small-group meeting designed around case-based clinical profiles and peer-dialogue led by an expert physician. This session offers practicing urologists the perfect opportunity to sharpen their skills and expertise in treatment strategies.
LEARNING OBJECTIVES
Location
MARKET RESEARCH PARTICIPATION
This event is held in partnership with Healthcare Research & Analytics (HRA®) to gain market research insights into health care professional’s educational needs in their current practice setting.
HRA® offers compensation of $500 to physicians for your consultative contributions during the event discussions, responses to polling questions and completion of a post-event survey.
Refer a physician colleague for an additional $150 referral bonus courtesy of Urology Times®. Please note that both you and your referral must attend the event and complete the post-event survey to qualify for the bonus.
Urology Times® — an MJH Life Sciences® Brand
Copyright 2025 © All Rights Reserved.